ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations
NCT ID: NCT01723878
Last Updated: 2017-09-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
144 participants
OBSERVATIONAL
2013-12-30
2017-06-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
NCT01250119
A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
NCT01310036
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.
NCT00773383
An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer
NCT01488331
An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)
NCT01512420
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically or cytologically confirmed locally advanced or metastatic (IIIB/IV) non-squamous non-small cell lung cancer (NSCLC) which is routinely evaluated in clinical practice according to RECIST criteria
* EGFR mutation-positive disease according to local laboratory testing
* Patients on treatment with Tarceva monotherapy as first-line treatment according to the physician's usual practice
Exclusion Criteria
* Participation in another clinical study
* Patients could have received radiotherapy as long as the irradiated lesion was not the only lesion for evaluating response and a long as the radiotherapy was completed before initiating Tarceva treatment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Virgen de los Lirios; Servicio de Oncologia
Alcoy, Alicante, Spain
Hospital Universitario Son Espases; Servicio de Oncologia
Palma de Mallorca, Balearic Islands, Spain
Hospital Son Llatzer; Servicio de Oncologia
Palma de Mallorca, Balearic Islands, Spain
Hospital General de Granollers; Servicio de Oncologia
Granollers, Barcelona, Spain
Hospital Mutua de Terrassa; Servicio de Oncologia
Terrassa, Barcelona, Spain
Hospital Universitario Puerta del Mar; Servicio de Oncologia
Cadiz, Cadiz, Spain
Hospital Universitario Marques de Valdecilla; Servicio de Oncologia
Santander, Cantabria, Spain
Hospital de Donostia; Servicio de Oncologia Medica
Donostia / San Sebastian, Guipuzcoa, Spain
Hospital Infanta Sofia; Servico de Oncologia
San Sebastián de los Reyes, Guipuzcoa, Spain
Hospital General de Lanzarote
Lanzarote, Las Palmas, Spain
Hospital de Gran Canaria Dr. Negrin; Servicio de Oncologia
Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital Universitario Principe de Asturias; Servicio de Oncologia
Alcalá de Henares, Madrid, Spain
Fundacion Hospital de Alcorcon; Servicio de Oncologia
Alcorcón, Madrid, Spain
Hospital del Henares; Servicio de Oncologia
Coslada, Madrid, Spain
Complejo Hospitalario de Orense; Servicio de Oncologia
Ourense, Orense, Spain
Hospital Meixoeiro
Vigo, Pontevedra, Spain
Hospital Univ. Central de Asturias
Oviedo, Principality of Asturias, Spain
Hospital Universitario de Canarias (HUC)
La Laguna (Tenerife), Tenerife, Spain
Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Oncologia
Santa Cruz de Tenerife, Tenerife, Spain
Hospital de Sagunto; Servicio de Oncologia
Sagunto, Valencia, Spain
Hospital Lluis Alcanys; Servicio de Oncologia
Xàtiva, Valencia, Spain
Hospital de Cruces; Servicio de Oncologia
Barakaldo, Vizcaya, Spain
Hospital Clinic de Barcelona
Barcelona, , Spain
Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
Barcelona, , Spain
Hospital Universitario Reina Sofia; Servicio de Oncologia
Córdoba, , Spain
Hospital Universitario San Cecilio; Servicio de Oncologia
Granada, , Spain
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia
Jaén, , Spain
Complejo Asistencial Universitario de Leon; Servicio de Oncologia
León, , Spain
Complejo Hospitalario Xeral-Cies
Lugo, , Spain
Hospital Universitario La Paz; Servicio de Oncologia
Madrid, , Spain
Hospital Universitario Puerta de Hierro; Servicio de Oncologia
Madrid, , Spain
Hospital Universitario de Mostoles;Servicio de Oncologia
Madrid, , Spain
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Hematologia
Málaga, , Spain
Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia
Murcia, , Spain
Hospital Clinico Universitario de Salamanca; Servicio de Oncologia
Salamanca, , Spain
Hospital General de Segovia; Servicio de Oncologia
Segovia, , Spain
Hospital Universitario Virgen Macarena; Servicio de Oncologia
Seville, , Spain
Hospital General de Teruel Obispo Polanco; Servicio Oncologia
Teruel, , Spain
Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia
Valencia, , Spain
Hospital Universitario Dr. Peset; Servicio de Oncologia
Valencia, , Spain
Hospital Clinico Universitario de Valladolid; Servicio de Oncologia
Valladolid, , Spain
Complejo Hospitalario Zamora- H. Virgen de la Concha; Servicio Oncologia
Zamora, , Spain
Hospital Universitario Miguel Servet; Servicio Oncologia
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML28361
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.